Glucagon

Generic Name: Glucagon

Brand Names: Baqsimi, Glucagen, Gvoke, Ogluo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 16941-32-5

Unique Ingredient Identifier: 76LA80IG2G

Background: Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication: Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions: Severe Hypoglycemia

Associated Therapies: -

Clinical Trials

Glucagon Regulation of Glucose Metabolism

Phase 1

Completed

Conditions: Insulin Secretion

Interventions: Drug: Glucagon

First Posted Date: 2020-04-15

Last Posted Date: 2021-05-14

Lead Sponsor: David D'Alessio, M.D.

Target Recruit Count: 19

Registration Number: NCT04347252

Locations: 🇺🇸
Duke Center for Living, Durham, North Carolina, United States

Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes

Phase 4

Completed

Conditions: Type 1 Diabetes
Hypoglycemia

Interventions: Device: Closed-loop system
Drug: Glucagon

First Posted Date: 2019-08-12

Last Posted Date: 2022-08-18

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 13

Registration Number: NCT04053712

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Biological: Glucagon
Other: Control Study

First Posted Date: 2019-05-28

Last Posted Date: 2024-11-26

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT03965130

Locations: 🇺🇸
Yale Hospital reserach Unit / YCCI, New Haven, Connecticut, United States

Intranasal Glucagon and Energy Balance

Phase 2

Conditions: Obesity

Interventions: Drug: Glucagon
Drug: Placebo

First Posted Date: 2018-08-28

Last Posted Date: 2018-08-31

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 20

Registration Number: NCT03650582

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

Phase 4

Completed

Conditions: Drug Overdose
Overdose of Beta-adrenergic Blocking Drug

Interventions: Drug: Esmolol
Drug: Glucagon
Drug: Physiologic saline - esmolol dummy
Drug: Physiologic saline - glucagon dummy

First Posted Date: 2018-05-23

Last Posted Date: 2019-10-17

Lead Sponsor: University Hospital Bispebjerg and Frederiksberg

Target Recruit Count: 10

Registration Number: NCT03533179

Locations: 🇩🇰
University Hospital Bispebjerg, Copenhagen, Denmark

Hepatic Metabolic Changes in Response to Glucagon Infusion

Not Applicable

Completed

Conditions: Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease
Total Pancreatectomy

Interventions: Drug: Saline
Drug: Glucagon

First Posted Date: 2018-05-16

Last Posted Date: 2019-08-06

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 27

Registration Number: NCT03526445

Locations: 🇩🇰
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Phase 2

Terminated

Conditions: Hypoglycemia Unawareness
Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Glucagon

First Posted Date: 2018-04-06

Last Posted Date: 2021-02-21

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT03490942

Locations: 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States

and more 2 locations

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: NNC9204-1513
Drug: Glucagon
Drug: Placebo

First Posted Date: 2018-02-23

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03444467

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

Phase 1

Completed

Conditions: Post-bariatric Hypoglycemia

Interventions: Drug: glucagon
Device: Closed loop glucagon pump

First Posted Date: 2017-08-21

Last Posted Date: 2022-09-06

Lead Sponsor: Joslin Diabetes Center

Target Recruit Count: 18

Registration Number: NCT03255629

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States

Liver Glycogen and Hypoglycemia in Humans

Phase 1

Active, not recruiting

Conditions: Hypoglycemia; Iatrogenic

Interventions: Drug: Saline
Drug: Low Fructose
Drug: Somatostatin
Drug: Insulin
Drug: Glucagon
Drug: High Fructose
Drug: Dextrose solution

First Posted Date: 2017-08-07

Last Posted Date: 2024-02-28

Lead Sponsor: Jason Winnick

Target Recruit Count: 40

Registration Number: NCT03241706

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy